Merck stock slid Tuesday after the company’s earnings failed to ease growing worries about the impending expiration of the ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

UnitedHealth shares continue to struggle after the company issued a fresh outlook for 2025, indicating revenue and adjusted ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

For key players in the sector, Eli Lilly has a median analyst target that’s 22% above its current share price. UnitedHealth Group is expected to rise by 18%, while Merck & Co. is forecasted 27% ...

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...

President Donald Trump is keeping up the pace with seemingly a new tariff development every day. This time, he flagged that ...

A cautious culture cost Novo its obesity lead Danish drugmaker Novo Nordisk was the first to sell a new generation of GLP-1 obesity drugs, but it’s now widely seen as trailing Eli Lilly. How did ...

April 21, 2025 — 08:17 am EDT Written by Zacks Equity Research for Zacks -> Eli Lilly (LLY) shares rallied 14.3% in the last trading session to close at $839.96.

Eli Lilly’s experimental cholesterol drug doubled patients’ HDL, or good cholesterol, setting the stage for a race between the Indianapolis pharmaceutical company and Merck and Roche Holding ...